Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 5/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9129690 | 1.00 | RAB9A (0.69) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL23223734 | 0.91 | RAB9A (0.69) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL11614936 | 0.91 | RAB9A (0.69) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL19209511 | 0.87 | ALDH1A1 (0.70) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL864257 | 0.86 | MAOB (0.67) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL13462927 | 0.86 | SMN1; SMN2 (0.75) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL4054280 | 0.86 | SMN1; SMN2 (0.75) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL4056179 | 0.86 | MAOB (0.67) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL9607336 | 0.85 | ALDH1A1 (0.79) | RAB9ANPC1TDP1ALDH1A1CYP2A6 | |
| SCHEMBL20000873 | 0.84 | APP (0.80) | RAB9ANPC1ALDH1A1APPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| EP-4126835-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| US-20220389036-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR?) AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-12-08 | — | — | US | disclosed |
| US-11447452-B2 | Agonists of peroxisome proliferator-activated receptor alpha and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
| US-20210024469-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2021-01-28 | — | — | US | disclosed |
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | KELLEHER JUDITH A (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6433008-B1 | TREATING PARKINSON*S, ALZHEIMER*S, AUTOIMMUNE AND RHEUMATIC DISEASES; HUMAN IMMUNODEFICIENCY VIRUS (HIV) DEMENTIA, AND INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1025079-A1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-08-09 | — | — | EP | disclosed |
| US-6046232-A | THERAPEUTICS FOR TREATING AND/OR PREVENTING NEUROLOGICAL, AUTOIMMUNE AND INFLAMMATORY CONDITIONS IN MAMMALS AND AS ANALYTICAL REAGENTS FOR DETECTING FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999020601-A1 | α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1994029287-A1 | ARYLIDENE-4-OXO-2-THIOXO-3-THIAZOLIDINE CARBOXYLIC AIDS, METHOD OF PREPARING THEM AND DRUGS CONTAINING SUCH COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | RAB9A 4220/4885NPC1 4460/4885TDP1 717/4885 |
| US-20210024469-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AND METHODS OF USE | PPARG, PPARA, PPARD | RAB9A 2886/4885NPC1 1872/4885TDP1 3044/4885 |
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | RAB9A 2194/4885NPC1 389/4885TDP1 218/4885 |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | RAB9A 2175/4885NPC1 196/4885TDP1 3116/4885 |
| US-11447452-B2 | Agonists of peroxisome proliferator-activated receptor alpha and methods of use | PPARG, PPARA, PPARD | RAB9A 2886/4885NPC1 1872/4885TDP1 3044/4885 |
| US-20220389036-A1 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR?) AND METHODS OF USE | PPARG, PPARA, PPARD | RAB9A 2817/4885NPC1 1631/4885TDP1 3204/4885 |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | RAB9A 2090/4885NPC1 400/4885TDP1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.